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Objectives: Our primary objective was to compare bioavailability and tolerability of a generic sustained-
release tablet with the established reference sustained-release tablet of diclofenac sodium in a fasting,
healthy Chinese male population.
Methods: A randomized, open-label, single- and multiple-dose study design was used. After the single
dose, volunteers received diclofenac sodium sustained-release tablet once daily for 5 days. In the single-
dose phase, blood samples were collected from 0 to 36 hours after drug administration. In the multiple-
dose phase, samples were obtained before drug administration at 8:00 AM on Days 3 and 4 to determine
Cmin,ss of diclofenac sodium; on Day 5, samples were collected from 0 to 36 hours. Adverse events were
monitored via subject interview, vital signs, and blood sampling.
Results: Twenty-four Chinese male volunteers were enrolled. The pharmacokinetic parameters (mean
[SD]) for diclofenac after single dose of 75 and 100 mg were: Cmax 473.5 [179.5] and 546.6 [154.9] ng/mL;
AUC0–1 3841.2 [1402.3], and 5019.1 [2,314.0] ng h/mL; Tmax 4.9 [2.4], and 4.3 [2.2] hours; t1/2 5.9 [2.5],
and 6.0 [2.2] hours. Mean [SD] values after multiple doses of 75 and 100 mg were: Cmax,ss 525.6 [127.4]
and 650.5 [167.0] ng/mL, Cmin,ss 33.9 [20.9] and 62.9 [34.9] ng/mL, AUCss 4316.3 [633.0] and 5335.1
[1291.9] ng h/mL, Cav,ss 179.8 [26.4] and 222.3 [53.8] ng/mL, Tmax 5.1 [1.8] and 4.5 [0.9] hours and t1/2 5.2
[2.9] and 5.5 [2.8] hours, respectively.
Conclusions: This diclofenac sodium 75 mg tablet has features compatible with the 100 mg sustained-
release tablet and appeared to be well tolerated. ClinicalTrials.gov identiﬁer: 2010L01969
Crown Copyright & 2013 Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are a preferred
therapy for osteoarthritis because they effectively relieve pain and
reduce inﬂammation with generally good tolerability.1–3 Diclofe-
nac is one of the most commonly used NSAIDs. It was approved in
the United States in 1988 for the treatment of patients with
osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis.4
It is an inhibitor of cyclooxygenase, and its potency is substantially
greater than that of indomethacin, naproxen, or several other
agents.5–7 It is one of the most prescribed NSAIDs worldwide.evier Inc.
partment of Pharmacy, Union
hnology, Jiefang St No.1277,
Open access under CC BY-NC-NDiclofenac, like all NSAIDs, is highly bound to human serum
proteins (Z99.5%), speciﬁcally albumin.8 It accumulates in syno-
vial ﬂuid after oral administration, which may explain the duration
of therapeutic effect that is considerably longer that the plasma
half-life.9 The half-life of diclofenac sodium in plasma varies from
1 to 3 hours. Peak plasma concentrations occur in about 3 hours.10
There are no data available on the distribution of diclofenac in
organs or tissues of human beings. Animal studies have shown
that the highest concentrations of diclofenac are found in bile,
liver, and kidneys followed by blood, heart, and lung.11,12 Diclofe-
nac undergoes extensive hepatic metabolism by cytochrome P-450
(CYP) 2C9 and CYP3A.13,14 CYP2C9 is polymorphic and is involved
in the oxidation of a wide range of drugs, including NSAIDs such as
naproxen, ibuprofen, and piroxicam.15,16
Diclofenac sodium has been marketed since 1973.17 Experi-
mental and clinical ﬁndings obtained to date have indicated that
diclofenac sodium was synthesized on well-founded principles.
Despite diclofenac sodium having been in widespread clinical use
for 420 years there is little published information on its pharma-
cokinetics of sustained-release tablet formulation in the ChineseD license.
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ature for reports on the pharmacokinetics of diclofenac identiﬁed
only a small number of pharmacokinetic studies in white sub-
jects.10 No reports were identiﬁed concerning the pharmacokinetic
properties of a sustained-release formulation of diclofenac sodium
in a Chinese population.
Although the branded diclofenac sodium sustained-release
tablet formulation was already marketed in China, information
regarding the pharmacokinetics of diclofenac and the bioequiva-
lence of these formulations in Chinese populations had seldom
been reported to date. Before allowing the marketing of generic
diclofenac sodium, the State Food and Drug Administration of
China requires pharmacokinetic studies of the bioequivalence of
generic and branded formulations. Therefore, the purpose of the
present single- and multiple-dose study was to compare the
bioavailability and tolerability of the proposed generic sustained-
release formulation with the established reference sustained-
release formulation of diclofenac sodium in a fasting, healthy
Chinese male population.Subjects and Methods
This was a single-center, randomized, open-label, 2-phase study
conducted to determine the pharmacokinetics of a generic
sustained-release formulation of diclofenac sodium after oral
administration of single and multiple doses in healthy Chinese
volunteers. This study was designed and conducted at Union
Hospital, Tongji Medical College, Huazhong University of Science
and Technology, Wuhan, People’s Republic of China, fromMay 2012
to June 2012. The study was conducted according to the principles
of the Declaration of Helsinki and its amendments for biomedical
research involving human subjects and the principles of the Good
Clinical Practice guidelines. The clinical trial was approved by the
State Food and Drug Administration of China (approval No.
2010L01969), and the clinical protocol and the informed consent
form were approved by the local ethics committee at Tongji
Medical College, Huazhong University of Science and Technology
(approval No. [2012]046). All eligible subjects were informed of the
aim and risks of the study by the clinical investigators and provided
written informed consent before participation.
Inclusion and exclusion criteria
Healthy, nonsmoking, male Chinese volunteers aged 20 to 30
years with a body mass index from 19 to 24 were enrolled in the
study. Before study entry, subjects were interviewed (regarding
their occupation, smoking and drinking habits, and medical
history) and underwent a routine physical examination, including
vital sign monitoring (ie, blood pressure, heart rate, respiratory
rate, and temperature), ECG, chest radiograph, and laboratory
analysis (ie, hematology, blood biochemistry, hepatic and renal
function, and urinalysis) to ensure that they were healthy enough
to participate in the study.
Subjects were excluded if they had a history or evidence of a
renal, gastrointestinal, hepatic, or hematologic abnormality; any
acute or chronic disease; or an allergy to any chemicals. Subjects
who had used drugs of any kind within the 2 weeks before the
start of or during the study were excluded, as were those who
consumed a moderate amount of ethanol daily (ie, 41 L beer or its
equivalent [50 g/d ethanol]).
Single-dose phase
Subjects were hospitalized at 10:00 PM the night before the
beginning of the study. They were randomly assigned, in a 1:1ratio using a computer-generated table of random numbers, to
receive a single dose of the test formulation (100 mg; lot No.
20110603, expiration date June 2013, Shenzhen Zhijun Pharma-
ceutical Co, Ltd, Shenzhen, China) or the reference formulation (75
mg; lot No. X0357, expiration date August 2013, Beijing Novartis
Pharma Co Ltd, Beijing, China) of diclofenac sodium sustained-
release tablets during Period 1 and the alternate formulation
during Period 2. The 2 periods of treatment were separated by a
7-day washout period.
In each treatment period, at 8:00 AM after the 12-hour
(overnight) fast and before administration of the study drug, an
indwelling venous catheter (Becton Dickinson Medical Devices Co,
Ltd, Suzhou, China) was placed in a suitable forearm vein, and a
5-mL blood sample was drawn into a vacuum tube with heparin
sodium (Tianjin Biochemical Pharmaceutical Factory Co, Ltd,
Tianjin, China). Then subjects were administered, under the super-
vision of study investigators, a single diclofenac sodium sustained-
release tablet orally with 250 mL water. Intake of food and
beverages (other than water, which was allowed after 2 hours)
was not permitted until 4 hours after drug administration; a
standardized lunch and dinner (200 g cooked rice, 200 g vegeta-
bles, 50 g pork, and 50 mL tomato soup) were provided at 4 and
9 hours after administration, respectively.
Additional blood samples were drawn at 0.5, 1, 2, 3, 5, 6, 8, 12,
14, 24, and 36 hours after drug administration. Plasma was
obtained by centrifugation at 1000 g for 10 minutes at 51C
(LDZ5-2 Auto-balance Table Centrifuge; Beijing Medical Centri-
fuges Ltd, Beijing, China) and stored at –801C until analyzed using
an LC-MS/MS method. Following the 7-day washout period after
administration of the initial formulation, the participants returned
to the study site, where the alternate formulation was adminis-
tered and samples were drawn and analyzed as before.
Multiple-dose phase
Volunteers assigned to the diclofenac sodium in the single-dose
phase continued into the multiple-dose phase, during which they
were conﬁned to the study center and received a diclofenac sodium
sustained-release tablet (75 mg or 100 mg QD at 8:00 AM) for
5 consecutive days. This dose was selected for the multiple-dose
phase because it is the dose likely to be used in clinical practice.
Samples of venous blood (5 mL each) were drawn from the
indwelling catheter before drug administration on Days 3 and 4 to
determine the Cmin,ss. On Day 5, blood samples were also drawn
at 0.5, 1, 2, 3, 5, 6, 8, 12, 14, 24, and 36 hours after drug
administration. All other experimental conditions were the same
as in the single-dose phase. Every period of treatment was
separated by a 7-day washout period throughout the experiment.
Intense physical activity, smoking, and consumption of bever-
ages containing xanthine derivatives or alcohol were not allowed
over the course of the study. Subjects were under continuous
medical supervision at the study site throughout the 5-week study
period.
Determination of plasma concentrations
The analysis of the concentrations of diclofenac in plasma was
conducted at Union Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, China, after the
completion of both periods. The concentration of diclofenac in
plasma was measured using a validated LC-MS/MS method. The LC-
MS/MS system was a Shimadzu LC-30AD pump (Shimadzu, Kyoto,
Japan), and a SIL-30AC autosampler (Shimadzu, Kyoto, Japan)
coupled to an API QTRAP 5500 triple quadrupole mass spectrom-
eter with an electrospray ionization source (AB/MDSSciex, Concord,
Ontario, Canada). The tandem mass spectrometer was operated
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spray ionization source in negative ion mode. The optimized
condition consisted of a collision-activated dissociation gas of the
medium, a curtain gas of 25 psi, a nebulizer gas of 50 psi, a
TurboIonSpray gas of 30 psi, an ionspray voltage of –4500 V, a
source temperature of 550˚C, and an entrance potential of –4 V for
diclofenac and –5 V for the internal standard (ie, indometacin).
Quantiﬁcation was operated in MRM of the transitions m/z 294.0
- m/z 250.0 for diclofenac, and m/z 356.1 - m/z 312.1 for
indometacin. MRM data was acquired and the chromatograms
were integrated with the software Analyst (version 1.6.1; AB Sciex,
Concord, ON, Canada).
An aliquot of 20 μL internal standard solution (indometacin
4920 ng/mL in mobile phase) and 20 μL menthol were added to a
200-μL plasma sample in a screw-cap glass tube. After vortex
mixing for 10 seconds, 500 μL acetonitrile was added to the
mixture to precipitate protein and the sample was vortex mixed
for 30 seconds and centrifuged at 13,000 revolutions/min at 41C
for 10 minutes; 150 μL of the upper layer was transferred to an
injection bottle, which was loaded into an autosampler cabinet
and 5 μL aliquot was injected into the LC-MS/MS system.
Chromatographic separation was performed on a Ultimate
XB-CN column (150 mm2.1 mm, 5mm, Welch Materials, Poto-
mac, MD). The mobile phase consisted of acetonitrile: 10 mM
ammonium formate containing 0.05% formic acid (70:30 v/v) at an
isocratic ﬂow rate of 0.3 mL/minute, the injection volume was
5 mL, and the run time was 4 minutes. The temperatures of the
analytical column and autosampler were set at 351C and 41C,
respectively. Under these conditions, the retention times for
diclofenac and indometacin were 2.5 minutes and 2.6 minutes,
respectively.
The method was shown to be suitable for the determination of
diclofenac in human plasma over the range of 8.3122 to 997.464
ng/mL (r Z 0.996). Using weighted least-squares regression, the
lower limit of quantitation was 8.3122 ng/mL plasma. Accuracy
measured at three concentration levels was acceptable (varied
from 95.23% to 99.97%) and the relative SD values were all
o5.67%. Precision was likewise acceptable (between 3.58% and
7.09%). The values of intraday and interday precision were o7.08%
at 3 concentration levels. Diclofenac and the internal standard
were stable in plasma at room temperature for at least 24 hours, as
well as for 84 days, at –801C after 3 freeze–thaw cycles.
The analytical method for diclofenac quantitation in plasma
samples was validated and applied to the bioequivalence study
according to international guidelines.18,19
Tolerability
Signs and symptoms of adverse effects of diclofenac sodium
such as gastrointestinal bleeding, ulceration, nausea, vomiting, as
well as any untoward effects, were collected using a daily written
questionnaire and recorded by the study physicians. Tolerability
was assessed using monitoring of vital signs (ie, blood pressure,
body temperature, heart rate, and respiratory rate), physical
examination, ECG, and routine blood and urine tests, along with
blood biochemical tests (hepatic and renal function), at the start as
well as at the end of the study. Blood pressure was measured using
a standard mercury sphygmomanometer on the left arm after
5 minutes’ rest, in the sitting position. In addition, vital signs were
assessed at 2, 4, 8, 24, and 36 hours after drug administration.
Adverse events were evaluated by the study physicians for
intensity, seriousness, and relationship to the study medication.
Adverse events were deﬁned as mild (awareness of a sign or
symptom but easily tolerated), moderate (discomfort sufﬁcient
to cause interference with normal activities), or severe (incapa-
citating, with an inability to perform normal activities). Causalitybetween the study drug and an adverse event was described by
the study physicians as “certainly,” “probably,” “possibly,” “sus-
pected,” or “not related.”
Pharmacokinetic and statistical analyses
Using a power analysis (expected value, Z1-β ¼ 0.8), it was
determined that the power of the ANOVA was 40.8 at a 90% CI
according to the US Food and Drug Administration guidelines on
bioequivalence testing,20 indicating that 24 subjects would be
sufﬁcient for the purposes of the study.
Single- and multiple-dose pharmacokinetic parameters were
calculated from the plasma concentration-time data by noncom-
partmental methods. Cmax and Tmax were obtained directly from
the observed data. The AUC0–t was calculated using the linear
trapezoidal rule.19 The AUC0–1 was calculated as AUC0–t þ Ct/λz,
where Ct is the last measurable concentration and λz is the slope of
the log-linear regression of the terminal concentration data
points.21 The t1/2 was calculated as (ln2)/λz. The mean concen-
tration at steady state (Css) was calculated as AUCss (0–τ)/τ.
To test the bioequivalence of the test and reference formula-
tions, ANOVA for the crossover design was conducted on
ln-transformed Cmax, AUC0–t, and AUC0–1. Before any comparisons
were performed, dose-dependent parameters (Cmax and AUC)
were normalized to the lower dose. The ratios of the
ln-transformed Cmax, AUC0–t, and AUC0–1 were calculated using
the F score. The probability of exceeding the limits of acceptance
for bioequivalence established by the FDA (80%–125%) was
obtained using two 1-sided t tests, as described by Schuirmann21
and the US Food and Drug Administration.22 The formulations
were to be considered bioequivalent if the ln-transformed ratios
(test/reference) of Cmax, AUC0–t, and AUC0–1 were within the
predetermined bioequivalence range of 80% to 125% and if the P
values were o0.05 for the 90% CIs.19,20
All pharmacokinetic analyses were conducted using Drug and
Statistics Software version 2.0 (Mathematical Pharmacology Pro-
fessional Committee of China, Shanghai, China).23 Individual
pharmacokinetic values were calculated and then the means
calculated. All statistical analyses were performed using SPSS
version 11.5 (IBM-SPSS Inc, Armonk, NY).Results
Subjects
A total of 24 subjects (mean [SD] age, 24.4 [2.3] years [range,
20–30 years]; weight, 63.6 [8.5] kg [range, 51.2–86.8 kg]; and
height, 1.72 [0.07] m [range, 1.57–1.91 m]) were enrolled in the
study. All subjects completed both treatment periods, with no
protocol violations.
Single-dose phase
Table I summarizes the mean [SD] pharmacokinetic parameters
of diclofenac sodium after single-dose administration of 2
sustained-release formulations in 24 healthy Chinese male volun-
teers. The mean Cmax for diclofenac with the test formulation was
11.786 [3.459] ng/mL and Tmax was 5.48 [2.06] hours. With the
reference formulation, the corresponding values were 11.754
[3.292] ng/mL and 6.26 [5.77] hours, respectively. The t1/2 values
with the test and reference formulations were 30.86 [7.61] and
30.96 [6.91] hours, respectively. The mean plasma concentration-
time proﬁles of the two sustained-release formulations (100 mg
for the test formulation and 75 mg for the reference formulation)
Table I
Mean [SD] pharmacokinetic parameters of diclofenac after administration of 2 sustained-release formulations (100 mg for the test formulation and 75 mg for the reference
formulation) of diclofenac sodium in 24 healthy Chinese male volunteers.
Parameter Single-dose administration Multiple-dose administration
Reference 75 mg (n ¼ 24) Test 100 mg (n ¼ 24) Reference 75 mg (n ¼ 24) Test 100 mg (n ¼ 24)
Mean [SD]
Cmax, ng/mL 473.5 [179.5] 546.6 [154.9] 525.6 [127.4] 650.5 [167.0]
Tmax, h 4.9 [2.4] 4.3 [2.2] 5.1 [1.8] 4.5 [0.9]
t1/2, h 5.9 [2.5] 6.0 [2.2] 5.2 [2.9] 5.5 [2.8]
AUC0–36, ng h/mL 3624.3 [1335.2] 4565.5 [1985.6] 4316.3 [633.0] 5335.1 [1291.9]
AUC0–1, ng h/mL 3841.2 [1402.3] 5019.1 [2314.0] 179.8 [26.4] 222.3 [53.8]
AUC0–36/AUC0–1 0.942 [0.047] 0.923 [0.067] 33.9 [20.9] 62.9 [34.9]
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shown in the Figure.
Multiple-dose phase
After administration of multiple oral doses of diclofenac
sodium (100 mg for the test formulation and 75 mg for the
reference formulation, QD for 5 days), there were no signiﬁcant
differences in Cmin between days 3, 4, and 5 (Table I), indicating
that steady-state conditions were achieved by Day 5 of multiple
dosing. Table II shows the mean pharmacokinetic parameters for800
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Figure. Mean [SD] plasma drug concentrations after administration of 2 sustained-rel
formulation, QD for 7 days) diclofenac sodium in 24 healthy Chinese male volunteers. (diclofenac after multiple-dose administration of 2 sustained-
release formulations. Under steady-state conditions, the mean
[SD] t1/2 was 6.24 [2.52] hours. The pharmacokinetic parameters
of diclofenac after multiple dosing were comparable to those after
single dosing, indicating no signiﬁcant accumulation of diclofenac
with repeated dosing. The mean concentration–time proﬁle after
administration of multiple oral doses of diclofenac sodium is
illustrated in the Figure.
Table II shows the 90% CIs of the ratios (test/reference) for the
ln-transformed values of pharmacokinetic parameters, as well as
the probability of exceeding the limits of acceptance forrugadministration (h)
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Reference formulation
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A) single-dose administration. (B) multiple-dose administration.
Table II
Comparison of 90% CIs for the ln-transformed ratios of pharmacokinetic parameters
of 2 sustained-release formulations of diclofenac sodium after single-dose and
multiple-dose administration in 24 healthy Chinese male volunteers; the prob-
ability of exceeding the limits of acceptance for bioavailability and power.
Parameter Ratio,
test/reference
90% CI P for exceeding the limits of
acceptance for bioavailability
Power
o80% 4125%
Single-dose administration
Cmax 89.6 82.1–97.8 o0.001 o0.001 0.99
AUC0–36 93.8 81.9–107.4 o0.001 o0.001 0.99
AUC0–1 95.9 83.2–110.6 o0.001 o0.001 0.99
Multiple-dose administration
Cmax 92.8 86.6–99.4 o0.001 o0.001 0.99
AUCss 91.3 84.2–99.1 o0.001 o0.001 0.99
X.-J. Zhai et al. / Current Therapeutic Research 75 (2013) 53–58 57bioavailability and the power of the test in the 24 healthy Chinese
male volunteers. The results could meet the predetermined criteria
for bioequivalence.
Tolerability
Diclofenac sodium appeared to be well tolerated by all volun-
teers. No adverse events were reported by subjects or found on
analysis of vital signs or laboratory test results. No abnormalities
were found in clinical or biochemical parameters when comparing
baseline versus end-of-study assessments.Discussion
Our study assessed the bioequivalence of single and multiple
doses of 2 sustained-release tablet formulations of diclofenac
sodium. There were no signiﬁcant differences between formula-
tions in pharmacokinetic properties in this small, selected, fasting,
healthy Chinese male volunteer population.
The peak plasma concentrations were lower and occurred later
after administration of either single or multiple doses of the
sustained-release formulation of diclofenac compared with the
normal tablet. Both formulations were apparently readily absorbed
from the gastrointestinal tract, and diclofenac was measurable at
the ﬁrst sampling time (at 0.5 hour). The mean plasma proﬁles and
bioavailability were similar both in single-dose and steady-state
pharmacokinetic analyses.
In our study, no period or sequence effects for any pharmaco-
kinetic property were found using ANOVA in the healthy Chinese
male volunteers. The absence of a sequence effect in both
pharmacokinetic parameters suggests that there was no carryover
effect for these 24 subjects. These results indicate that a washout
period of 7 days was adequate for total elimination of the drug
between the 2 administration periods.
Our study found that the use of the sustained-release diclofenac
sodium tablets under investigation might be suitable for therapeu-
tic use, administered once a day. The adverse events reported in
literatures were not related to higher peaks in plasma concen-
tration of test formulation of diclofenac sodium in our study.
No subject withdrew from our study, and no adverse events
were found on analysis of vital signs or laboratory test results.
However, the study was limited by its short duration; its inclusion
of only healthy male volunteers under fasted conditions; and by its
single- and multiple-dose, open-label design. The mean age of
these healthy subjects was 24.2 years (range, 20–30 years) and,
therefore, the study results cannot be extrapolated to an older
population. The results also cannot be used to predict performance
in patients in clinical practice.Conclusions
Our single- and multiple-dose study found that the test and
reference formulations of diclofenac sodium met the regulatory
criteria for bioequivalence in these fasting, healthy Chinese male
volunteers. Both formulations appeared to be well tolerated.Acknowledgments
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